Shots:
- Daiichi Sankyo has dosed the first patient in the P-I trial with DS1025 for the treatment of advanced or metastatic solid tumors with disease progression on or after ≥1 prior line of standard therapy
- The P-I trial of DS1025 will evaluate safety, tolerability, PK & preliminary efficacy above-mentioned pts (n=~45), assessing safety & tolerability, incl. dose-limiting toxicities & AEs as the 1EP
- DS1025 is a CD25-directed ADC using Daiichi Sankyo’s DXd technology to deliver an immuno-oncology payload designed to deplete immunosuppressive Treg cells and activate the immune system against cancer cells
Ref: Businesswire | Image: Daiichi Sankyo | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
